PL3630114T3 - Migalastat do leczenia pacjentów z chorobą Fabry'ego z zaburzeniem czynności nerek - Google Patents

Migalastat do leczenia pacjentów z chorobą Fabry'ego z zaburzeniem czynności nerek

Info

Publication number
PL3630114T3
PL3630114T3 PL18733415.6T PL18733415T PL3630114T3 PL 3630114 T3 PL3630114 T3 PL 3630114T3 PL 18733415 T PL18733415 T PL 18733415T PL 3630114 T3 PL3630114 T3 PL 3630114T3
Authority
PL
Poland
Prior art keywords
migalastat
renal impairment
fabry patients
treating fabry
treating
Prior art date
Application number
PL18733415.6T
Other languages
English (en)
Inventor
Jeff Castelli
Original Assignee
Amicus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65803261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3630114(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.
Priority claimed from PCT/US2018/035032 external-priority patent/WO2018222655A1/en
Publication of PL3630114T3 publication Critical patent/PL3630114T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL18733415.6T 2017-05-30 2018-05-30 Migalastat do leczenia pacjentów z chorobą Fabry'ego z zaburzeniem czynności nerek PL3630114T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762512458P 2017-05-30 2017-05-30
US201862626953P 2018-02-06 2018-02-06
PCT/US2018/035032 WO2018222655A1 (en) 2017-05-30 2018-05-30 Methods of treating fabry patients having renal impairment

Publications (1)

Publication Number Publication Date
PL3630114T3 true PL3630114T3 (pl) 2024-03-25

Family

ID=65803261

Family Applications (4)

Application Number Title Priority Date Filing Date
PL22165669.7T PL4062916T3 (pl) 2017-05-30 2018-05-30 Leczenie pacjentów z chorobą Fabry’ego mających pewne mutacje
PL23219933.1T PL4327869T3 (pl) 2017-05-30 2018-05-30 Sposoby leczenia pacjentów z chorobą Fabry’ego mających zaburzenie czynności nerek
PL23219949.7T PL4324522T3 (pl) 2017-05-30 2018-05-30 Sposoby leczenia pacjentów z chorobą Fabry’ego mających zaburzenie czynności nerek
PL18733415.6T PL3630114T3 (pl) 2017-05-30 2018-05-30 Migalastat do leczenia pacjentów z chorobą Fabry'ego z zaburzeniem czynności nerek

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PL22165669.7T PL4062916T3 (pl) 2017-05-30 2018-05-30 Leczenie pacjentów z chorobą Fabry’ego mających pewne mutacje
PL23219933.1T PL4327869T3 (pl) 2017-05-30 2018-05-30 Sposoby leczenia pacjentów z chorobą Fabry’ego mających zaburzenie czynności nerek
PL23219949.7T PL4324522T3 (pl) 2017-05-30 2018-05-30 Sposoby leczenia pacjentów z chorobą Fabry’ego mających zaburzenie czynności nerek

Country Status (14)

Country Link
EP (9) EP3630114B9 (pl)
CN (4) CN111278438A (pl)
DK (4) DK4324522T3 (pl)
ES (5) ES3002433T3 (pl)
FI (4) FI4062916T3 (pl)
HR (4) HRP20260346T1 (pl)
HU (2) HUE069837T2 (pl)
LT (4) LT4324522T (pl)
PL (4) PL4062916T3 (pl)
PT (4) PT4062916T (pl)
RS (4) RS67861B1 (pl)
SI (4) SI4327869T1 (pl)
SM (4) SMT202600114T1 (pl)
TW (4) TWI894750B (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220313670A1 (en) * 2019-06-11 2022-10-06 Amicus Therapeutics, Inc. Methods Of Treating Fabry Disease In Patients Having Renal Impairment
KR20220044560A (ko) * 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
MX351004B (es) * 2006-05-16 2017-09-26 Nat Institutes Of Health Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
EP2142197A4 (en) 2007-03-30 2010-11-10 Amicus Therapeutics Inc METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES
AU2008245578A1 (en) * 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2009102895A2 (en) * 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
WO2012125402A2 (en) * 2011-03-11 2012-09-20 Amicus Therapeutics, Inc. Dosing regimens for the treatment of fabry disease
US20120283290A1 (en) * 2011-05-06 2012-11-08 Amicus Therapeutics Inc. Quantitation of gl3 in urine
WO2018017721A1 (en) 2016-07-19 2018-01-25 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naïve and ert-experienced patients
AU2018277756A1 (en) 2017-05-30 2020-01-23 Amicus Therapeutics, Inc. Methods of treating fabry patients having renal impairment
EA202090242A1 (ru) * 2017-07-19 2020-05-26 Амикус Терапьютикс, Инк. Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов

Also Published As

Publication number Publication date
TWI775453B (zh) 2022-08-21
DK3630114T3 (da) 2024-01-29
RS67849B1 (sr) 2026-03-31
SI4062916T1 (sl) 2025-04-30
EP4327869A3 (en) 2024-05-22
TW201900165A (zh) 2019-01-01
HRP20240061T1 (hr) 2024-03-29
EP4324522A2 (en) 2024-02-21
CN119587544A (zh) 2025-03-11
EP4635496A1 (en) 2025-10-22
ES2970419T3 (es) 2024-05-28
EP4062915A1 (en) 2022-09-28
HUE069837T2 (hu) 2025-04-28
CN117357524A (zh) 2024-01-09
FI4324522T3 (fi) 2026-03-09
DK4324522T3 (da) 2026-03-16
SI3630114T1 (sl) 2024-03-29
LT4327869T (lt) 2026-03-25
PT4327869T (pt) 2026-03-12
SMT202400037T1 (it) 2024-03-13
EP4245366A9 (en) 2023-12-06
FI3630114T3 (fi) 2024-01-30
DK4062916T3 (da) 2025-01-13
FI4062916T3 (fi) 2025-01-10
EP4245366A2 (en) 2023-09-20
RS66376B1 (sr) 2025-02-28
EP4327869B1 (en) 2025-12-10
SMT202500016T1 (it) 2025-03-12
ES3052647T3 (en) 2026-01-12
EP4374918B1 (en) 2025-07-16
HUE065615T2 (hu) 2024-06-28
EP4245366A3 (en) 2023-11-29
PL4062916T3 (pl) 2025-03-17
EP4062916A1 (en) 2022-09-28
FI4327869T3 (fi) 2026-03-09
TWI795408B (zh) 2023-03-11
TWI894750B (zh) 2025-08-21
SMT202600114T1 (it) 2026-05-12
SMT202600113T1 (it) 2026-05-12
PT4324522T (pt) 2026-03-13
EP3630114B9 (en) 2026-05-20
HRP20260335T1 (hr) 2026-04-10
HRP20241738T1 (hr) 2025-02-28
EP4324522A3 (en) 2024-05-22
LT4324522T (lt) 2026-03-25
PT3630114T (pt) 2024-02-01
RS65230B1 (sr) 2024-03-29
LT3630114T (lt) 2024-02-12
EP4327869A2 (en) 2024-02-28
EP4374918A3 (en) 2024-08-14
EP4062916B1 (en) 2024-10-09
PL4327869T3 (pl) 2026-04-27
ES3002433T3 (en) 2025-03-06
PT4062916T (pt) 2025-01-13
ES3065434T3 (en) 2026-05-06
TW202440104A (zh) 2024-10-16
EP4374918A2 (en) 2024-05-29
SI4327869T1 (sl) 2026-05-29
EP3630114B1 (en) 2023-11-01
LT4062916T (lt) 2025-01-10
TW202322814A (zh) 2023-06-16
EP3630114A1 (en) 2020-04-08
CN111278438A (zh) 2020-06-12
SI4324522T1 (sl) 2026-05-29
PL4324522T3 (pl) 2026-04-27
CN120732857A (zh) 2025-10-03
EP4324522B1 (en) 2025-12-10
EP4327868A2 (en) 2024-02-28
DK4327869T3 (da) 2026-03-16
HRP20260346T1 (hr) 2026-04-24
TW202140000A (zh) 2021-11-01
RS67861B1 (sr) 2026-04-30
ES3065413T3 (en) 2026-05-06

Similar Documents

Publication Publication Date Title
GB201813876D0 (en) Treatment
GB201800546D0 (en) Treatment
GB201709093D0 (en) Patient monitoring system
GB201802795D0 (en) Patient assessment method
ZA201805245B (en) Method for treating cancer patients with severe renal impairment
PL3612475T3 (pl) Instalacja obróbkowa
GB201707910D0 (en) Patient monitoring system
PL3668563T3 (pl) Cewnik do dializy
SG11202102878TA (en) Treatment methods
SG11202102827YA (en) Treatment methods
GB201604658D0 (en) Treatment for pain
ES3065434T3 (en) Methods of treating fabry patients having renal impairment
GB201717555D0 (en) Blood filter
GB201718985D0 (en) Treatment
IL287840A (en) treatment system
PL3730200T3 (pl) Ulepszony system filtrów
HUE049399T2 (hu) Mandzsetta ortopédiai kezeléshez
GB201710360D0 (en) Patient monitoring
GB201812463D0 (en) Preparation for nasal-nasopharyngeal treatment
GB201814905D0 (en) Treatment
GB201802269D0 (en) Handbarrow for carrying patients
ZA201801814B (en) Patient assessment
GB201713650D0 (en) Treatment
GB201711677D0 (en) Combination treatment
GB201706955D0 (en) Treatment